aceclofenac (CID 71771) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(5)
 
 
Inactive(644)
 
 
Inconclusive(27)
 
 
Unspecified(135)
 
 
Top Targets:
7TM GPCR Srx(29)
 
 
 
p450(18)
 
 
 
 
7TM GPCR Srsx(16)
 
 
 
TRP 2(5)
 
 
Geminin(4)
 
 
BioAssay Types:
Screening(336)
 
 
Confirmatory(230)
 
 
 
 
 
Literature(87)
 
 
 
 
BioActivity Types:
Potency(175)
 
 
 
 
 
IC50(157)
 
 
 
 
 
EC50(4)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 716    Data Row: 811   Total Pages: 17   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103303791]
IC50 1.288DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) [AID625208, Type: other]Aldose reductase [gi:1168407]
View
2
[SID11112873]
Potency 1.5849qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9 [AID883, Type: confirmatory]cytochrome P450, family 2, subfamily C, polypeptide 9 [Homo sapiens] [gi:13699818]
View
3
[SID11112873]
Potency 1.5849qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9 [AID883, Type: confirmatory]cytochrome P450, family 2, subfamily C, polypeptide 9 [Homo sapiens] [gi:13699818]
View
4
[SID11112873]
Potency 1.5849qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9 [AID883, Type: confirmatory]cytochrome P450, family 2, subfamily C, polypeptide 9 [Homo sapiens] [gi:13699818]
View
5
[SID103303791]
IC50 5.927DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) [AID625181, Type: other]Mitogen-activated protein kinase 1 [gi:119554]
View
6
[SID103303791]
IC50 5.927DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) [AID625181, Type: other]Mitogen-activated protein kinase 1 [gi:119554]
View
7
[SID103303791]
IC50 5.927DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) [AID625181, Type: other]Mitogen-activated protein kinase 1 [gi:119554]
View
8
[SID11112873]
 Cytochrome panel assay with activity outcomes [AID1851_5, Type: other]cytochrome P450, family 2, subfamily C, polypeptide 9 [Homo sapiens] [gi:13699818]
View
9
[SID11112873]
 Cytochrome panel assay with activity outcomes [AID1851_5, Type: other]cytochrome P450, family 2, subfamily C, polypeptide 9 [Homo sapiens] [gi:13699818]
View
10
[SID50085951]
 Aqueous Solubility from MLSMR Stock Solutions [AID1996, Type: other]
View
11
[SID11112873]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749, Type: Literature]
View
12
[SID103303791]
 Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis [AID592681, Type: Literature]
View
13
[SID103303791]
IC50 DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) [AID625158, Type: other]
View
14
[SID103303791]
 DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) [AID625164, Type: other]
View
15
[SID103303791]
IC50 DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625165, Type: other]
View
16
[SID103303791]
IC50 DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625166, Type: other]
View
17
[SID103303791]
 DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) [AID625169, Type: other]
View
18
[SID103303791]
IC50 DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) [AID625170, Type: other]
View
19
[SID103303791]
 DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) [AID625189, Type: other]
View
20
[SID103303791]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) [AID625190, Type: other]
View
21
[SID103303791]
IC50 DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) [AID625197, Type: other]
View
22
[SID103303791]
IC50 DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) [AID625210, Type: other]
View
23
[SID103303791]
 DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) [AID625211, Type: other]
View
24
[SID103303791]
IC50 DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) [AID625212, Type: other]
View
25
[SID103303791]
IC50 DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) [AID625215, Type: other]
View
26
[SID103303791]
IC50 DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) [AID625216, Type: other]
View
27
[SID103303791]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) [AID625219, Type: other]
View
28
[SID103303791]
IC50 DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) [AID625224, Type: other]
View
29
[SID103303791]
IC50 DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) [AID625225, Type: other]
View
30
[SID103303791]
 DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) [AID625230, Type: other]
View
31
[SID103303791]
IC50 DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) [AID625234, Type: other]
View
32
[SID103303791]
IC50 DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) [AID625260, Type: other]
View
33
[SID103303791]
IC50 DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) [AID625261, Type: other]
View
34
[SID103303791]
IC50 DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) [AID625262, Type: other]
View
35
[SID103303791]
IC50 DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) [AID625264, Type: other]
View
36
[SID103303791]
 DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) [AID625265, Type: other]
View
37
[SID103303791]
IC50 DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653) [AID625266, Type: other]
View
38
[SID103303791]
IC50 DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP) [AID625267, Type: other]
View
39
[SID103303791]
IC50 DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) [AID625268, Type: other]
View
40
[SID103303791]
IC50 DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) [AID625272, Type: other]
View
41
[SID103303791]
 DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) [AID625274, Type: other]
View
42
[SID103303791]
IC50 DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) [AID625275, Type: other]
View
43
[SID103303791]
IC50 DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) [AID625172, Type: other]Progesterone receptor [gi:75071465]
View
44
[SID103303791]
 Anticonvulsant activity [AID227700, Type: Literature]
View
45
[SID103303791]
IC50 DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) [AID625144, Type: other]Leukotriene C4 synthase [gi:239977155]
View
46
[SID103303791]
IC50 DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) [AID625209, Type: other]Type-2 angiotensin II receptor [gi:1703214]
View
47
[SID103303791]
IC50 DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625247, Type: other]Cytochrome P450 2C19 [gi:60416369]
View
48
[SID103303791]
IC50 DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625247, Type: other]Cytochrome P450 2C19 [gi:60416369]
View
49
[SID11112873]
 Cytochrome panel assay with activity outcomes [AID1851, Type: other]cytochrome P450, family 2, subfamily C, polypeptide 19 [Homo sapiens] [gi:4503219]
View
50
[SID11112873]
 Cytochrome panel assay with activity outcomes [AID1851, Type: other]cytochrome P450, family 2, subfamily C, polypeptide 19 [Homo sapiens] [gi:4503219]
View